Companion Animal Welfare

Dog Canine Mast Cell Tumour Advanced Welfare

Advanced mast cell tumour management integrates targeted therapy, quality of life assessment, and palliative care for dogs with this common skin cancer.

Key Facts

Mast cell tumours are the most common malignant skin tumour in dogs
Tyrosine kinase inhibitors (toceranib, masitinib) provide effective targeted therapy for c-kit mutated tumours
Grade determines biological behaviour more than location in most cases
Palliative treatment with prednisolone and diphenhydramine controls systemic effects of mast cell degranulation
Quality of life rather than survival time is increasingly the primary treatment goal

Welfare Considerations

Advanced mast cell tumour management that integrates targeted therapy, quality of life assessment, and palliative care provides dogs with the best possible welfare outcomes through their cancer journey.

What You Can Do

Seek specialist oncology assessment for dogs with mast cell tumour diagnosis
Discuss targeted therapy options if c-kit mutation testing is positive
Prioritise quality of life assessment in all treatment decisions for cancer dogs